Read this company snapshot
Daily valuation snapshot
XTL Biopharmaceuticals Ltd. American Depositary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $1.98
- Market capitalization (USD)
- $4,683,904.61
- Price / earnings (TTM)
- Not reported
- Price / book
- Not reported
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research XTLB in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research XTLB in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing XTLB with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $1.98 |
| Market capitalization (USD) | $4,683,904.61 |
| Price / earnings (TTM) | Not reported |
| Price / book | Not reported |
No matching rows. Clear the filter to see all records.
Read XTLB's valuation metrics
Company size
XTL Biopharmaceuticals Ltd. American Depositary Shares's recorded market capitalization is $4,683,904.61. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
Price-to-book compares market equity value with recorded book equity. Intangible assets, profitability and the company's business affect how useful the comparison is.
Research XTL Biopharmaceuticals Ltd. American Depositary Shares with Aurora
Use the snapshot above to ask a specific question about XTLB. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow XTLB's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.